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Patient-speciﬁc modellingCardiac resynchronisation therapy (CRT) is an established treatment for heart failure, however the effective
selection of patients and optimisation of therapy remain controversial.While extensive research is ongoing, it re-
mains unclear whether improvements in patient selection or therapy planning offers a greater opportunity for
the improvement of clinical outcomes. This computational study investigates the impact of both physiological
conditions that guide patient selection and the optimisation of pacing lead placement on CRT outcomes. A
multi-scale biophysical model of cardiac electromechanics was developed and personalised to patient data in
three patients. These models were separated into components representing cardiac anatomy, pacing lead loca-
tion,myocardial conductivity and stiffness, afterload, active contraction and conduction block for each individual,
and recombined to generate a cohort of 648 virtual patients. The effect of these components on the change in
total activation time of the ventricles (ΔTAT) and acute haemodynamic response (AHR)was analysed. The pacing
site location was found to have the largest effect on ΔTAT and AHR. Secondary effects on ΔTAT and AHR were
found for functional conduction block and cardiac anatomy. The simulation results highlight a need for a greater
emphasis on therapy optimisation in order to achieve the best outcomes for patients.
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100Table 1
Demographics and baseline clinical indices for the patients in this study. (QRSd: QRS du-
ration, EF: ejection fraction, EDV: end diastolic volume)
Cases Sex Age QRSd (ms) EF (%) EDV (ml)
1 M 63 188 23.5 310
2 F 81 139 24.7 172
3 M 77 171 19.6 3311. Introduction
Heart failure (HF) is a signiﬁcant disease in the western world, af-
fecting 1−2% of the adult population and accounting for around 2% of
all healthcare spending [1]. Cardiac Resynchronisation Therapy (CRT)
is an effective treatment for dyssynchronous HF [2], reducing the risk
of hospitalisation and death, and leading to improved heart function
and quality of life [2–4]. However, using the current selection criteria
of left ventricle (LV) dysfunction (LV ejection fraction (EF) ≤35%) and
electrical dyssynchrony (QRS duration (QRSd) 120−149 with left bun-
dle branch block (LBBB) or QRSd ≥150) [5], only 67% of patients beneﬁt
from CRT, while 39% of patients receiving standard pharmacological
therapy improve without CRT [6].
The improvement of patient selection for CRT is therefore an impor-
tant area of research, so that optimal outcomes for patients are achieved
without unnecessary application of this expensive and invasive therapy.
Patient physiology and demographic factors such as sex [7], diabetes [8]
and ischaemia [9] have been shown to affect the potential beneﬁts of
CRT. Clinical research has also demonstrated the potential for improved
response to CRT by optimisation of pacing lead location [10–12].
In this paper, we investigatewhether either of the confounding roles
of patient physiology or optimisation of CRT pacing lead location has a
greater inﬂuence on patient outcomes. To systematically quantify the
impact of each mechanism on patient response, we adopt a patient-
speciﬁc computational modelling approach. Personalised biophysical
modelling of cardiac function has increasingly been used to investigate
the mechanisms underlying CRT response, and demonstrate its poten-
tial for advanced treatment planning [13–17]. We have constructed
personalised and validated computational models of three CRT patients.
These models were used to generate a virtual patient cohort, in which
the relative impact of patient physiology and device placement on the
total activation time (TAT) of the ventricles and acute haemodynamic
response (AHR) was evaluated in silico.
2. Methods
2.1. Model development and personalisation
Eachmodel consists of a biventricular, weakly coupled [18]model of
cardiac electromechanics, combining a monodomain model of tissue
electrophysiology using the ten Tusscher model of cellular electrophys-
iology [19] with a model of large deformation mechanics using the
Guccione passive material law [20], a phenomenological model of
myocardial active tension [16] and a 3 element Windkessel model of
afterload. The complete modelling framework is described in detail in
Section 1 of the online supplement accompanying this article. Models
were personalised using clinical data, as outlined below and described
in detail in Section 2 of the supplement.
2.1.1. Cardiac anatomy and ﬁbres
A tricubic Hermite description of the cardiac anatomywas ﬁtted to a
manually or automatically segmented end diastolicmagnetic resonanceimaging (MRI), as described previously [21,22]. A generic ﬁbre ﬁeld
based on a priori knowledge was mapped to each patient-speciﬁc ana-
tomical model [16], and an additional high resolution tetrahedral
discretisation was generated from each cubic Hermite mesh for the
purposes of simulation of electrophysiology. Section 2.1 of the online
supplement describes this process in detail.
2.1.2. Electrical activation
Sinus rhythm (SR) activation was simulated by applying a stimulus
current at the earliest sites of activation in the septum and RV as deter-
mined from ECG and EnSite™ non-contact mapping (NCM) data, and
from the literature [23] in the case of the location of the earliest activa-
tion in the RV. The timings of these intrinsic stimuli were determined
relative to the time of sinoatrial depolarisation as a reference point.
CRT activation was simulated by adding electrical stimuli at pacing
lead locations in the RV apex and LV epicardium determined from an-
giograms registered with MRI [24]. Following the clinical protocol,
leadswere paced 100ms after sinoatrial node activation, prior to the ac-
tivation of the intrinsic stimuli. Conduction block was included by
means of a region of low conductivity, with its location determined
from NCM. Activation sequences were validated by comparison with
NCM activation maps. For additional details on the above steps, see
Section 2.2 of the online supplement.
2.1.3. Contraction
Simulation of the full cardiac cycle was carried out at SR and with
CRT by mapping simulated depolarisation times to the cubic Hermite
computational mesh, where they are used as an input to the active ten-
sion model. 2 parameters from the passive material law, 6 parameters
from the active tension model and the 3Windkessel model parameters
were ﬁtted to patient-speciﬁc pressure-volume (PV) loops at sinus
rhythm and to the observed acute haemodynamic response (AHR) in
the case of the active tension model. Mechanical contraction was
validated by comparison with short axis cine MRI at sinus rhythm.
Section 2.3 of the online supplement describes this process in detail.
2.1.4. Patient cases
The personalisation workﬂow summarised above and described in
detail in the online supplement was applied to three patients with
demographics and baseline characteristics as shown in Table 1. All
patients had a dilated cardiomyopathy (DCM) aetiology and NYHA
class of III.
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Simulations of cardiac electrophysiology were run with the Cardiac
Arrhythmia Research Package (CARP) (http://carp.medunigraz.at/),
developed at the Medical University of Graz (Graz, Austria) and the
University of Bordeaux (Bordeaux, France). Simulations were per-
formed on ARCHER (http://www.archer.ac.uk/), the UK national high
performance computing (HPC) resource, using 288 cores and requiring
2.5−4 h execution time permodel. Large deformation mechanics were
simulated using CMISS (http://www.cmiss.org/), developed at the Uni-
versity of Auckland (Auckland, New Zealand), and executed on the HPC
resource at the Department of Biomedical Engineering at King's College
London, using 4 cores and requiring 14−20 h execution time per
model.
2.2. Virtual patient cohort
A virtual patient cohort (VPC) was generated from combinations of
discretemodel components fromeach of the three personalisedmodels.
In the ﬁrst virtual patient cohort (VPC1), model inputs were separated
into 6 components: model geometry, including both the cardiac anato-
my and the location of the pacing leads; tissue conductivity; the pres-
ence of conduction block; tissue stiffness; Windkessel model; and
active tension model parameters. Generating models for all possible
combinations of these 6 components resulted in a VPC of 486 models
(2 possible values for the binary ‘presence of conduction block’ compo-
nent, and 3 possible values for the 5 other components).
As VPC1 did not allow the differentiation of the effects of cardiac
anatomy and CRT pacing lead location, a supplementary second virtual
cohort (VPC2)was generated. In VPC2, pacing lead locations and cardiac
anatomy were considered independently, while the tissue stiffness,
Windkessel model and active tension model parameters for each
patient were combined into a single ‘mechanical model parameters’
component to retain computational tractability of the VPC as a whole.
This resulted in 5 components: cardiac anatomy; tissue conductivity;
conduction block; pacing lead location; andmechanical model parame-
ters. The VPC generated from all potential combinations of these com-
ponents contained 162 models (2 possible values for the ‘presence of
conduction block’ component, and 3 possible values for the others as
above).
The pacing lead locations were readily mapped between anatomies
in VPC2 by use of the cubic Hermite mesh. These structured meshes
had a consistent topology, and so pacing locations were mapped
betweenmeshes by ﬁrst evaluating their position in the internal localﬁ-
nite element coordinate space of the mesh of the source case, then
reevaluating the Cartesian coordinate in the mesh of the destination
case.
2.2.1. Simulations
Simulations of cardiac contraction were performed for all of the
models in both VPCs at SR and with CRT. This required a total of 36
simulations of electrophysiology (EP) and 972 simulations of large
deformation mechanics for VPC1, and 108 simulations of EP and 324
simulations of mechanics for VPC2. The number of EP simulations re-
quired was smaller than the number of mechanics simulations in both
VPCs, as the tissue stiffness, Windkessel model and active tension
model have no effect on EP in our weakly coupled framework. In total,
223 thousand core hours were utilised on ARCHER and the Department
of Biomedical Engineering HPC while executing these simulations.
2.2.2. Metric calculation
Twometricswere calculated for eachmodel: the fractional change in
the total activation time of the ventricles (TAT) on pacing (ΔTAT), and
the acute haemodynamics response (AHR). Changes in TAT are consid-
ered clinically important, as electrical resynchronisation of the ventri-
cles by CRT is expected to be measured by a decrease in TAT. AHR is
the fractional increase in the maximum rate of pressure developmentin the LV on pacing, and has been used in the clinic as a measure of
acute response to therapy and as a predictor of long term remodelling
[25]. Thesemetrics are both relevant to the functional changes expected
to be brought on by CRT, and are directly comparable to clinical studies.
Both metrics were calculated for each model generated in VPC1 and
VPC2 above.
2.3. Detection of effects
Differences caused by individual model components were identiﬁed
by dividing a VPC into groups by the source of a given component, and
identifying important differences in the above clinical metrics between
these groups. Since VPC1 and VPC2 were not samples of a normally dis-
tributed population, conventional statistical tests of such changes were
not applicable. Instead, boxplots ofΔTAT and AHRwere plotted for each
group, and inter-group differences caused by the component in ques-
tion identiﬁed by either
• two groups having a non-overlapping inter-quartile range (IQR); or
• N30% of data points of one group lying outside the boxplotwhiskers of
another group.
Boxplots were plotted with thewhiskers extending to 1.5 times the IQR
past the ﬁrst and third quartiles. Beyond the whiskers, data points are
considered outliers and are plotted individually. Correlations between
ΔTAT and AHR were evaluated with the non-parametric Spearman's
rank correlation coefﬁcient.
3. Results
3.1. Model personalisation
Anatomicalmodelswere generated fromMRI for three patient cases,
and are shown in Fig. 1. Fig. 2 summarises the parameter ﬁtting and val-
idation of 3 models of cardiac electromechanics to patient data using
our personalisation workﬂow as described above.
The electrical conductivity parameters of each casewere ﬁtted to the
QRS duration at SR, and validated by comparison of LV endocardial acti-
vation timemapswith NCM (Fig. 2a). Due to discrepancies between the
NCM-derived and MRI-derived endocardial geometries, and the appli-
cation of the system in ventricles larger than its validated range [26],
it was not possible to perform a quantitative validation of the simulated
activation time maps. However, a qualitative comparison showed that
the model provides a good representation of the endocardial activation
pattern in all cases.
Passive tissue stiffness, Windkessel model parameters and active
tension model parameters were ﬁtted to patient-speciﬁc PV data at SR
and AHR with CRT (Fig. 2b), and validated by comparison of predicted
myocardial deformations with short axis cine MRI (Fig. 2c).
3.2. Virtual patient cohort
Virtual patient cohorts were generated as outlined in Section 2.2,
and the fractional change in TAT due to pacing (ΔTAT) and the AHR
were evaluated for each model.
3.2.1. VPC1
Fig. 3 shows the distribution of ΔTAT and AHR for eachmodel in the
ﬁrst virtual patient cohort (VPC1), separated into subgroups by each
model component.
Based on the criteria outlined in Section 2.3, the cardiac anatomyand
pacing lead location, tissue conductivity and conduction block were all
found to have an important effect on changes in TAT due to pacing. Sim-
ilarly, the cardiac anatomy and pacing lead location, conduction block
and active contractionmodel parameters were found to have an impor-
tant effect on AHR. The importance of tissue conductivity in ΔTAT was
not repeated with AHR.
1 2 3
Fig. 1. Personalised ﬁnite element meshes, derived from end Diastolic MRI, for the three patient cases in this study.
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blockwere particularly notable. Fig. 4 compares the AHRwith andwith-
out conduction block for otherwise equivalent models in VPC1. This ﬁg-
ure shows that, despite a large variation in AHR within the virtual
cohort, 97.1% of otherwise equivalent models had a greater AHR with
conduction block than without.
The results also showed that the cardiac anatomy and pacing lead lo-
cation had an important effect on both changes in TAT with pacing and
AHR. The separate contribution of each of these two factors is studied in
VPC2, as reported in the next section.
3.2.2. VPC2
LV pacing lead locations were mapped between patient anatomies
as described in Section 2.2, and are shown mapped to a single case in
Fig. 5.
Fig. 6 shows the distribution of ΔTAT and AHR for each model in the
second virtual patient cohort (VPC2), separated into subgroups by
model component.
Based on the criteria outlined in Section 2.3, both the cardiac anato-
my and pacing lead location were found to have an important effect on
changes in TAT due to pacing. Cardiac anatomy, conduction block, pac-
ing lead location and mechanical model parameters were found to
have an important effect on AHR. Pacing lead location was seen to be
the strongest effect detected in our analysis in either virtual cohort,
based on the number of inter-group difference tests described in
Section 2.3 passed.
This resultwas supported by an analysis of the range of AHRpossible
in isolatedmodels by changing a singlemodel component. Changing the
pacing location yielded the largest AHR change when averaged across
all models in VPC2, of 18.4%, whereas the next largest, the mechanical
parameters, had an average range of 12.1%.
WhileΔTATwas not found to be strongly affected by the presence of
conduction block in VPC2, it was found that it still had a strong effect on
AHR. In addition, we observed that cardiac anatomy and in particular
the pacing lead locations had a strong effect on both ΔTAT and AHR. In
order to consider the potential link between effects on ΔTAT and AHR,
we analysed the correlation between these metrics. Fig. 7 shows how
for all models in VPC2 there was a strong negative correlation between
the change in TAT on pacing and AHR, with a Spearman's rank correla-
tion coefﬁcient of−0.73.
4. Discussion
Through the creation of two virtual patient cohorts by combining
components of three personalised electromechanical models of CRT,
we have analysed the effect of cardiac anatomy, pacing lead location,
myocardial conductivity and stiffness, afterload, active contraction and
conduction block on simulated acute outcomes. In VPC1, our results
showed that both the presence of conduction block and active contrac-
tion model parameters have an important effect on the response to
therapy, as measured by the change in TAT on pacing and by AHR. Sim-
ilarly, the cardiac anatomy and pacing lead locationswere both found to
be important in VPC2.4.1. Consequences for patient selection
The signiﬁcance of the active contraction model parameters is un-
derstandable given their role in translating myocardial activation into
pump function, and indeed is consistent with previous research [16].
However, since these parameters remain challenging to reliably mea-
sure in a clinical context, it is unlikely that theywould be used in clinical
patient selection without the addition of a comprehensive modelling
study.
The importance of conduction block for predicting CRT outcomes is
of more clinical utility. Patients with conduction block experienced
both greater reductions in TAT on pacing and improved AHR, a result
which has also been observed in the clinic [27,28]. While in this study
the presence of conduction block was established from an invasive
study, preclinical assessment of activation pattern by reconstruction
frombody surface ECG [29]mayprovide an additional tool for improved
prediction of patient response and selection for therapy.
The effect of cardiac anatomyon the response to therapy is less clear,
as the potential variations in cardiac anatomy are clearly not fully ex-
plored by three cases. Observed differences betweenmodels of different
anatomymay be partially explained by differences in heart size, howev-
er a greater diversity of cardiac anatomies is required to identify what
features affect response.
It was also found that there was a negative correlation between the
change in TAT with pacing and AHR. This supports the general principle
of CRT, which is that electrical resynchronisation, quantiﬁable as a re-
duction in TAT with pacing, results in improved cardiac performance
and reverse remodelling, as predicted by AHR [25]. However, the suit-
ability of AHR for the prediction of long term outcomes and the link be-
tween ΔTAT and AHR remains controversial [30–33].
Nevertheless, the observed relationship between ΔTAT and AHR
provides an explanation for the inﬂuence of conduction block and cardi-
ac anatomy on AHR. Both of these properties modify the distance that
must be traversed by the depolarisation wavefront in each cardiac
cycle, and hence affect the measured TAT and its change with pacing.
Models with greater reductions in TAT with pacing then experience a
greater AHR.4.2. Consequences for therapy optimisation
Pacing lead locationswere also found to have an important effect on
both changes in ΔTAT and AHR.While the above reported effect of con-
duction block has signiﬁcance for the selection of appropriate patients
for therapy, this ﬁnding highlights the relevance of improved lead
placement. The observed differences in ΔTAT and AHR by pacing lead
location demonstrate the importance of optimising CRT lead placement
for achieving the best possible outcome to therapy.
The effect of pacing site on AHRwas again attributed to the observed
relationship betweenΔTAT andAHR.With optimal choice of pacing site,
TAT can be reduced, and AHR consequently improved. However, while
this connection is supported by some literature [32,34,35], it remains
controversial [33,36]. Indeed, our analysis suggests that positive AHR
is not guaranteed by a reduction in TAT. While all models in VPC1
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Fig. 2. Parameter ﬁtting and validation. (A) Tissue conductivity was ﬁtted to sinus rhythmQRS duration and validated by visual comparison of simulated endocardial activation timemaps
(right)with EnSite non-contactmapping (NCM)data (left). Contours on the simulated activation timemaps are displayed at 20 intervals, however these are not shownon thenon-smooth
maps from NCM, which are displayed registered with the MRI-based anatomical model for reference. (B) Tissue stiffness, Windkessel model and active tension model parameters were
ﬁtted to patient-speciﬁc pressure-volume data at sinus rhythm and (C) validated by comparison of simulated deformations with short axis cine MRI.
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Fig. 3. Boxplots showing the distribution of changes in TAT due to pacing and in AHR,
when the ﬁrst virtual patient cohort (VPC1) was separated into subgroups by each of 6
model components. Boxplots are not shown for changes in TAT for the tissue stiffness,
Windkessel model and active contraction model components, as these components have
no effect on the simulation of cardiac electrophysiology. Boxplot whiskers extend 1.5
times the IQR past theﬁrst and third quartiles, and outlying points are shownwithmagen-
ta crosses.
Fig. 4. Comparison of AHR with and without conduction block for otherwise equivalent
models in the ﬁrst virtual patient cohort (VPC1). Most models can be seen to lie above
the line of unity, with 97.1% having a better AHR when conduction block was present.
1
3
2
Fig. 5. The location of the LV pacing lead was mapped to an equivalent anatomic position
in other cases by use of theﬁtted cubic Hermitemesh, as described in Section 2.2. Here the
pacing lead locations (blue, numbers correspond to lead source case) are shown mapped
to the anatomy of case 3.
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reduction in TAT of up to 27.8%, due to the confounding effects of other
parameters.
These results posed the further question of whether therapy optimi-
sation is required on a patient-speciﬁc basis, or whether there is a com-
mon optimal pacing location across cases. The most successful pacing
location, that from case 1, was positioned in the lateral wall, seen both
in experiments [37] and in the clinic [38] to produce the strongest pac-
ing response. In contrast, the pacing locations from cases 2 and 3 were
on the anterior wall, seen to result in weaker responses.
We compared sets ofmodels fromVPC2which varied only by pacing
location, but whose other components remained the same, and found
that while the pacing location from case 1 provided the greatest AHR
in 88.5% of cases, in the remaining 11.5% the location from case 3 was
superior. While this echoes the results from Fig. 6, it also shows that a
single pacing location was not best in all instances. This is perhaps not
surprising, given the high variability in the patient population. Hetero-
geneity of tissue conductivity, contractility or other factors in the myo-
cardium may make certain areas unsuitable for pacing. Indeed, in the
models where the case 3 pacing location provided the best AHR, all
had conduction block.While it was not possible to determine the variability of the location
of the absolute optimal pacing location in this study, our results suggest
that it will not be the same in all cases, and may be dependent on spe-
ciﬁc characteristics of individual patients. In addition, since the choice
of pacing location is constrained by the coronary venous anatomy
when using a transvenous delivery system [38], the need for therapy
optimisation on a patient-speciﬁc basis is ever more apparent.
4.3. Focus for maximising response
In this paper we focus on the question of whether improved patient
selection or therapy optimisation is more important for maximising
outcomes to CRT. While model components relevant to both selection
and optimisation are important, pacing lead locations had the strongest
Fig. 6. Boxplots showing the distribution of changes in TAT due to pacing and in AHR,
when the second virtual patient cohort (VPC2) was separated into subgroups by each of
5 model components. Boxplots are not shown for changes in TAT for the mechanical
model component, as it has no effect on the simulation of cardiac electrophysiology.
Boxplot whiskers extend 1.5 times the IQR past the ﬁrst and third quartiles, and outlying
points are shown with magenta crosses.
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ment planning may therefore improve overall outcomes of CRT com-
pared to improved patient selection alone. Our results suggest thatFig. 7. Correlation between changes in TAT on pacing and AHR for all models in the second
virtual patient cohort (VPC2). A negative correlation was found, with a Spearman's rank
correlation coefﬁcient of−0.73.lead placement optimisation should be prioritised if we are to gain the
best possible beneﬁt from CRT.
New technologies that allowCRTwithmultiple LV leads [39] or free-
dom of pacing site by pacing on the endocardium rather than in the cor-
onary vasculature [40] may also beneﬁt from this conclusion. The
variation of CRT efﬁcacy with pacing site could be readily exploited by
these technologies, which have greater ﬂexibility to achieve optimal
therapy outcomes in individuals and the population.
4.4. Limitations
The models provide a simpliﬁed representation of patient cardiac
function. Fig. 2b shows that the model provided a relatively poor ap-
proximation of diastole, while providing a better description of systole,
which was the period of interest in this study. The ﬁndings here are
generated from three patients whohad high quality and detailed exper-
imental measurements, which limited the development of a larger
number of personalised models. However, the analysis of three
personalised models represents a signiﬁcant advance in the coverage
of the patient population when compared to previous work, which
analysed a single patient case [16,17]. While these patients are repre-
sentative of DCM, these conclusions should be interpreted with caution
for cohorts of ischaemic patients, since none of the cases considered
presented scar.
The development of VPCs allowed analysis of a more diverse cohort,
however it should be recognised that not all individuals are necessarily
realistic. However, all models had a realistic EF for DCM at sinus rhythm
of between 13% and 26%, offering a reasonable ﬁrst order guarantee that
the 648 generated models are valid. While the VPCs cannot be guaran-
teed to be statistically equivalent to an actual patient group, they pro-
vide a plausible representation of CRT patients. The conclusions drawn
were observed consistently across the cohort and are therefore held to
be representative.
4.5. Conclusions
The presence of conduction block was identiﬁed as an indicator for
response to CRT, highlighting its potential utility for patient selection
alongside other criteria. Pacing lead locationswere also found to strong-
ly affect response to therapy, which demonstrated the importance of
the optimisation of CRT lead placement. While model components rele-
vant to both patient selection and lead optimisation affected response to
CRT, pacing lead locations were found to have the strongest inﬂuence.
We therefore concluded that improved treatment planning should be
prioritised in order to maximise CRT outcomes.
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